Polycythemia Vera


Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.
Related to Polycythemia Vera: Polycythemia rubra vera

polycythemia vera

[‚päl·i‚sī′thē·mē·ə ′vir·ə]
(medicine)
An absolute increase in all blood cells derived from bone marrow, especially erythrocytes.

Polycythemia Vera

 

(also erythremia, Vaquez’ disease), a chronic disease of the hematopoietic system first described by the French physician L. H. Vaquez in 1892. Polycythemia vera is characterized by an increase in erythrocyte, leukocyte, and platelet mass and in plasma volume. It is classified as a form of leukemia. The course of the disease is comparatively benign. The principal symptoms are a dark red coloration of the skin, elevated blood pressure, proneness to hemorrhaging and thrombosis, and enlargement of the spleen.

Cytological analysis of bone marrow is an important aid in diagnosis. Treatment includes phlebotomy and the administration of cytostatics.

REFERENCE

Vorob’ev, A. I., M. D. Brilliant. Patogenez i terapiia leikozov. Moscow, 1976.
Mentioned in ?
References in periodicals archive ?
Clinical profile of homozygous JAKV>2 V617F mutation in patients with polycythemia vera or essential thrombocythemia.
The Polycythemia Vera Study Group (PVSG) was organized in 1967 to identify the optimal approach to the diagnosis and treatment of PV (Streiff et al.
1,2] Based on the results of the first study conducted by the Polycythemia Vera Study Group, Landaw concluded that acute leukemia is part of the natural history of PV, occurring in 2 of 134 patients treated with phlebotomy alone (1%-2%).
Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera.
For over 50 years, HU has been used in the treatment of chronic myeloproliferative disorders, such as chronic myeloid leukemia, polycythemia vera, and ET (3).
The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera.
Splenic rupture complicating periinterventional glycoprotein IIb/IIIa antagonist therapy for myocardial infarction in polycythemia vera.
The most common BCRJABL1-negative MPNs are polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).
We hope that this inhibitor and similarly functioning molecules might lead to new drugs against the fatal disease polycythemia vera, which currently has no therapies," said Dr.
Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group.